Why the study?
Does renin-angiotensin-aldosterone system inhibition improve renal and cardiovascular outcomes in patients with chronic kidney disease?
Does renin-angiotensin-aldosterone system inhibition improve renal and cardiovascular outcomes in patients with chronic kidney disease?
RAAS inhibition with ACEIs and ARBs provides significant renal and cardioprotection in patients with chronic kidney disease.
Answers are grounded in this paper and cite their sources.
Supports RAAS inhibition in CKD for renal/CV protection; leaves open optimal combinations and dosing in advanced stages.
Chronic kidney disease (CKD) is emerging as a new health pandemic. Underlying the global rise in CKD is an increase in diabetes, hypertension and other cardiovascular risk factors leading to progressive renal dysfunction. Emerging evidence strongly suggests that achieving target blood pressure goals via inhibition of the renin-angiotensin-aldosterone system confers significant renal and cardioprotection for patients with CKD. Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) lower blood pressure, reduce proteinuria and reduce both the progression of CKD and adverse cardiovascular events. The role of aldosterone inhibition and combination therapy, such as ACEI/ARB, in CKD are under investigation. As our understanding of the basic mechanisms underlying CKD progression advances, novel therapies targeting post-translational endothelial and mesangial messengers downstream from angiotensin II and aldosterone may become available for clinical use.
No takes yet. Share an insight, caveat, or question.
Norris et al. (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: